| Not Yet Recruiting | B7-H3.CD28Z.CART in CNS Neoplasms NCT07390539 | Robbie Majzner | Phase 1 |
| Not Yet Recruiting | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline NCT06639607 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Not Yet Recruiting | Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors NCT07424092 | Clinica Universidad de Navarra, Universidad de Navarra | Phase 2 |
| Not Yet Recruiting | Pharmacoscopy for Patients With Refractory Primary Brain Tumors NCT06804655 | University of Zurich | Phase 2 |
| Not Yet Recruiting | Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refracto NCT07061626 | Plus Therapeutics | Phase 1 |
| Active Not Recruiting | Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Gra NCT07031765 | University of Florida | Phase 1 |
| Not Yet Recruiting | Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas NCT06323408 | University Hospital Regensburg | — |
| Active Not Recruiting | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer NCT06521567 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Recruiting | Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline NCT06779487 | Tata Memorial Centre | — |
| Not Yet Recruiting | Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and NCT06485908 | Assistance Publique Hopitaux De Marseille | Phase 1 / Phase 2 |
| Recruiting | Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) NCT06193759 | Children's National Research Institute | Phase 1 |
| Not Yet Recruiting | In Vitro Models From Pediatric Brain Tumors NCT06499636 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications NCT06161519 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO) NCT06038760 | Ourotech, Inc. | — |
| Recruiting | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors NCT05835687 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-N NCT05259605 | European Organisation for Research and Treatment of Cancer - EORTC | — |
| Recruiting | Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China NCT05672043 | Beijing Tiantan Hospital | — |
| Active Not Recruiting | HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma NCT04903080 | Children's Oncology Group | Phase 1 |
| Active Not Recruiting | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma an NCT04978727 | Children's Oncology Group | Phase 1 |
| Recruiting | Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma NCT05057702 | University of California, San Francisco | N/A |
| Recruiting | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer NCT05106296 | Theodore S. Johnson | Phase 1 |
| Terminated | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and You NCT04730349 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Active Not Recruiting | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, NCT04661384 | City of Hope Medical Center | Phase 1 |
| Recruiting | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms NCT04541082 | Jazz Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF NCT04374305 | Scott R. Plotkin, MD, PhD | Phase 2 |
| Terminated | Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma NCT03727841 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Mid NCT04185038 | Seattle Children's Hospital | Phase 1 |
| Active Not Recruiting | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG NCT04049669 | Theodore S. Johnson | Phase 2 |
| Withdrawn | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain o NCT03990597 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Social Determinants of Health in Glioblastoma Population NCT03900689 | Wake Forest University Health Sciences | — |
| Recruiting | LET Optimized IMPT in Treating Pediatric Patients With Ependymoma NCT03750513 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS NCT03638167 | Seattle Children's Hospital | Phase 1 |
| Active Not Recruiting | HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumor NCT03500991 | Seattle Children's Hospital | Phase 1 |
| Completed | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies fo NCT03434262 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology NCT04648462 | Maastricht Radiation Oncology | — |
| Completed | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy f NCT03194906 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children NCT03043391 | Istari Oncology, Inc. | Phase 1 |
| Completed | Rare CNS Tumors Outcomes &Risk NCT03251989 | National Cancer Institute (NCI) | — |
| Active Not Recruiting | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 NCT03152318 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers NCT03173950 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors NCT03095248 | Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Completed | HUMC 1612: Optune NovoTTF-200A System NCT03128047 | Hackensack Meridian Health | Phase 1 |
| Active Not Recruiting | Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With NCT03033992 | Children's Oncology Group | N/A |
| Withdrawn | Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas NCT02976441 | Washington University School of Medicine | EARLY_Phase 1 |
| Withdrawn | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors NCT02689336 | Washington University School of Medicine | Phase 2 |
| Terminated | Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine NCT02722512 | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 1 |
| Completed | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primar NCT02502708 | NewLink Genetics Corporation | Phase 1 |
| Completed | Molecular-Guided Therapy for Childhood Cancer NCT02162732 | Giselle Sholler | N/A |
| Active Not Recruiting | A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma NCT02125786 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Study of SBRT Efficacy on Intra and Extra -Cranial Tumors or Metastasis in Pediatrics Population (SBRT Pediatr NCT02013297 | Centre Leon Berard | N/A |
| Completed | Study of the Effect of GM-CSF on Macrophages in Ependymoma NCT04408092 | University of Colorado, Denver | EARLY_Phase 1 |
| Terminated | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors NCT01836549 | Pediatric Brain Tumor Consortium | Phase 2 |
| Terminated | Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod NCT01795313 | James Felker | Phase 1 |
| Completed | Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma NCT01498783 | St. Jude Children's Research Hospital | Phase 1 |
| Terminated | Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 NCT01247922 | OSI Pharmaceuticals | Phase 2 |
| Completed | Carboplatin and Bevacizumab for Recurrent Ependymoma NCT01295944 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors NCT01331135 | Emory University | Phase 1 |
| Completed | Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation NCT01288235 | Massachusetts General Hospital | Phase 2 |
| Completed | Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ep NCT02238899 | Universitätsklinikum Hamburg-Eppendorf | — |
| Completed | Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor NCT01171469 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Active Not Recruiting | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Pat NCT01096368 | Children's Oncology Group | Phase 3 |
| Withdrawn | A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas NCT01117155 | National Cancer Institute (NCI) | — |
| Terminated | Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma NCT01088035 | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 2 |
| Completed | A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With NCT00994071 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Methionine PET/CT Studies In Patients With Cancer NCT00840047 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | A Study of Pemetrexed in Children With Recurrent Cancer NCT00520936 | Eli Lilly and Company | Phase 2 |
| Completed | Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors NCT01445288 | National Cancer Institute (NCI) | — |
| Completed | Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors NCT00919750 | Children's Oncology Group | — |
| Terminated | Antineoplaston Therapy in Treating Patients With Ependymoma NCT00003479 | Burzynski Research Institute | Phase 2 |